Sampling performance of EUS-Guided fine-needle biopsy in pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Juan Manuel Millan-Alanis, Luis Andrés González-Torres, Joel Omar Jáquez-Quintana et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the sampling performance of EUS-guided fine-needle biopsy (FNB) in patients with suspected pancreatic neuroendocrine tumors (PNETs). Analyzing data from 12 studies with 846 patients, FNB achieved adequate tissue sampling in 89% of cases and allowed Ki-67 assessment in 96%. The study highlights FNB's advantages over fine-needle aspiration (FNA) for diagnostic purposes.
Key findings
- FNB achieved adequate tissue sampling in 89% of cases.
- Ki-67 proliferative index assessment was possible in 96% of cases.
- Diagnostic concordance with surgical specimens was 82%.
- The Sharkcore needle showed the highest performance among FNB devices.
Why it matters
Accurate tissue acquisition is crucial for diagnosing and grading pancreatic neuroendocrine tumors, which can influence treatment decisions. Understanding the effectiveness of FNB compared to FNA can guide clinicians in selecting appropriate biopsy techniques.
What to keep in mind
Risk of bias was moderate to high across several domains, and the certainty of evidence ranged from moderate to very low.